Stocktoria
Monopar Therapeutics MNPR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-12-19
Monopar Therapeutics financials (annual, from 10-K)
| Metric | FY2025 | FY2025 | FY2025 | FY2025 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $9.9M | — | — | — | $13.0M |
| Operating income | -$16.7M | — | — | — | -$16.2M |
| Income tax | $800 | — | — | — | $800 |
| Net income | -$13.7M | — | — | — | -$15.6M |
| Operating cash flow | -$12.2M | — | — | — | -$6.4M |
| Cash & equivalents | $61.8M | $127.7M | $39.5M | $39.7M | $45.8M |
| Total assets | $140.7M | $144.2M | $53.9M | $55.1M | $60.3M |
| Total liabilities | $2.9M | $2.6M | $1.7M | $1.5M | $5.3M |
| Shareholders' equity | $137.8M | $141.6M | $52.2M | $53.6M | $55.0M |
Source: SEC EDGAR filings · CIK 0001645469 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.